Form 4: Alnylam Pharmaceuticals Executive Kevin Fitzgerald Reports Stock Sales and Option Exercises

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reported the sale of common stock and exercise of stock options on August 12, 2024, according to a Form 4 filing.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, filed a Form 4 detailing transactions in Alnylam common stock on August 12, 2024.
• Fitzgerald exercised stock options to acquire 6,667 shares at $97.72 and 14,058 shares at $85.
• He sold a total of 21,825 shares of common stock at prices ranging from $268.66 to $274.65.
• These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on May 10, 2024.
• Following these transactions, Fitzgerald directly owns 12,881 shares of common stock and indirectly owns 537 shares through a managed account.
• He also holds 2,192 stock options with an exercise price of $85 and 0 stock options with an exercise price of $97.72.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans to sell shares over time.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Executives commonly use Rule 10b5-1 trading plans to diversify their holdings and avoid accusations of insider trading.
• The volume of shares sold is relatively small compared to the overall market capitalization of Alnylam Pharmaceuticals.

Key Dates